RecruitingSquamous Cell Carcinoma of Head and Neck
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Eligible age
18–100 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
Sponsor: University of Arkansas
You may qualify if…
- ✓ Able to provide informed consent
- ✓ Male or female 18 years of age or older
- ✓ Squamous cell carcinoma of the head and neck who have completed curative therapy (surgery and/or radiation and/or chemotherapy and/or immunotherapy) within the 120 days prior to the screening visit
- ✓ No Evidence of Disease (NED) based on clinical and radiographic evaluations
- ✓ Willing and able to comply with the requirements of the protocol
You may not qualify if…
- ✕ Positive urine pregnancy test for women of childbearing potential
- ✕ Being pregnant or attempting to be pregnant with the period of study participation
- ✕ Women who are breast feeding or plan to breast feed within the period of study participation
- ✕ Patients who are allergic to Candin®
- ✕ If in the opinion of the PIs or other Investigators, it is not in the best interest of the patient to enter or continue in this study
Where it's recruiting
Source: ClinicalTrials.gov · NCT05952934 · last updated 2026-04-08